Blue Horseshoe Stocks: Big Options Gainers & More

SPDR S&P500 ETF (SPY) – Recap

Yesterday morning in our premarket report, we formulated a fresh options idea with the SPY 05/15 $281-282.50 Calls after seeing that market conditions appeared to be gearing up for another session-over-session reversal after Monday’s selloff.

Our hunch proved accurate, with a bullish session similar to Friday’s going on the books yesterday, and it provided for some nice chances in our highlighted contracts.

$281 Calls – Range: 2.13-4.35 – Max Gain: 104%
$281.50 Calls – Range: 1.87-3.85  – Max Gain: 106%
$282 Calls – Range: 1.55-3.39 – Max Gain: 119%
$282.50 Calls – Range: 1.30-3.03  – Max Gain: 133%


Amplitech Group, Inc. AMPG – News

We’re revisiting AMPG again for the third straight time this week, after the company’s quarterly report was released yesterday, containing highlights for Q1 2019, which included bolstered sales, profits, and cash on hand. 

Some of the key financial highlights were as follows:

-Sales were $678.3K, up from $428.5K a year earlier, an improvement of $249.8K, or 58.3%

-Gross profits were $324.1K, up from $254.9K a year earlier, an improvement of $69.2K, or 27.1% Gross margins in Q1 were 47.8%, down from 59.5% the prior year.

-Operating Income in Q1 increased to $82.6K, up from $44.2K a year earlier, an improvement of $38.4K, or 86.9%

-Earnings before interest, tax, depreciation and amortization (EBITDA) for Q1 increased to $119.7K from $52.1K the prior year, an increase of $67.6 thousand, or 129.8%  EBITDA margins for the current quarter were 17.6 percent vs 12.2 percent in 2018, an improvement of 44.3 percent.

-Cash on hand increased from $442.1K in Q1 of 2018 to $783.6K in 2019, helped by improved profits as well as a new term debt facility which was secured in the first quarter. (>>View Full PR)

Be sure to check out the recent acquisition news from AMPG as well, which figures to improve the company’s sales by a significant margin.


FRESH OPTIONS IDEA:
Macy’s, Inc. M Weekly $22-23.50 Calls


Extended Watchlist:
CLRB, XXII, CEI, TLGT, HIIQ, HTBX, PEIX

Blue Horseshoe Stocks: Recent Winners


Recapping Recent Hot Picks

First thing’s first- we would like to include a quick update on two of the stocks to appear in our report yesterday, in which we had already witnessed very nice gains.  Both stock pressed to new highs during yesterday’s session, so we wanted to update readers on their continued success.

Tandem Diabetes Corp. TNDM  –  We called TNDM initially on April 11th, whereupon we observed a low of 6.62.  Yesterday the stock rose another 12% intraday, running from 10.75 to 12.05. That new high represents an 82% jump since our first alert, just over a month ago.

Stein Mart, Inc. SMRT – Also appearing in yesterday’s report for having put up impressive figures following our March 16th alert and subsequent observed low of 1.33, was SMRT. The stock reached a notable new high of 3.94. marking a two-month uptrend amounting to 196%



Arcadia Biosciences, Inc. RKDA

To come back to yet another great call we made last Tuesday (05/08), we’ve got RKDA. A couple of sessions following that first call, the stock would register a low of 7.31, and this week, we’re seeing the stock reaching new heights.

Yesterday it hit 12.25, which marks a rise of 67% in a matter of just six trading days. There is still a lot of room to the upside on the chart for RKDA to travel, so we’re definitely going to keep our eyes peeled for further bullish activity from RKDA.

Heat Biologics, Inc. HTBX

Speaking of charts with potential, we tagged HTBX on Monday, and it has been trending in the right direction, trading up from 1.35 to 1.74 so far. As you can see on the provided snapshot, it still has a very ripe-looking chart.



Extended Watchlist:
ARLZ, BLNK, BOOT, HEAR, M

Blue Horseshoe Stocks: ALDX Review & More

Aldeyra Therapeutics, Inc. ALDX

The big standout from yesterday morning’s premarket report turned out to be ALDX, which initially drew our attention with an abnormal volume signal, and the release of positive Phase 2a study data for a Dry Eye Disease treatment.

The stock recorded a continuously bullish pattern throughout the day, trading in an impressive range. From it’s early morning low of 6.60, the stock reached a high of 11.05 just prior to the closing bell. That’s an increase 67% on the day, on more than twenty times the monthly average volume. It also easily took the top gainer spot on the NASDAQ board for the session.

ALDX increasing in value by two-thirds in a single session worked well for us yesterday, but such moves also rare and often unsustainable events. It’s difficult to imagine a scenario where the stock doesn’t undergo a consolidation in the session or sessions to come.


Macy’s, Inc. M – Options Review

We want to swing back around for a recap of the performance in a set of Macy’s calls we made a few weeks ago as a longer-term options idea. Typically, when a stock seems set for an extended rebound, we’ll signal contracts whose expiration doesn’t occur for a longer period of time. In this case we highlighted the

It worked out nicely, with M stock making a steady increase over these last few weeks that facilitated a move in those calls from .60-1.37, which comes out to a respectable gain of 128%

______

Fresh Idea:

We also look for quick strike chances as well, and may have one with Mirati Therapeutics, Inc. MRTX today after the stock soared following the presentation of positive cancer trial data at a conference in Chicago.

We’ll be looking for a dip-and-rip pattern off of this morning’s significant premarket gap-up, and will be tracking the MRTX Weekly $7.50 Calls* and possibly even the $10’s if it appears as if MRTX wants to break that ten dollar barrier.

*Never attempt to trade weekly options on a Friday unless you are A.) An expert trader and B.) Have money you can afford to lose. It’s an extremely risky proposition.


Extended Watchlist:
LPTH, ARRY, MBOT, ATOS, RXII